Comparative Pharmacology
Head-to-head clinical analysis: TAPENTADOL versus WESTADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TAPENTADOL versus WESTADONE.
TAPENTADOL vs WESTADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tapentadol is a centrally acting analgesic with a dual mechanism of action: mu-opioid receptor agonist and norepinephrine reuptake inhibitor.
Mu-opioid receptor agonist; also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake.
Immediate-release tablets: 50-100 mg orally every 4-6 hours as needed for pain; maximum 600 mg per day. Extended-release tablets: 50-250 mg orally twice daily (every 12 hours); maximum 500 mg per day.
Oral: 2.5-10 mg every 4-6 hours as needed for pain; maximum 40 mg per day.
None Documented
None Documented
Terminal elimination half-life is approximately 4 hours (range 3-5 hours) for immediate-release; for extended-release, effective half-life is about 4-6 hours due to prolonged absorption.
Clinical Note
moderateTapentadol + Torasemide
"The risk or severity of adverse effects can be increased when Tapentadol is combined with Torasemide."
Clinical Note
moderateTapentadol + Etacrynic acid
"The risk or severity of adverse effects can be increased when Tapentadol is combined with Etacrynic acid."
Clinical Note
moderateTapentadol + Furosemide
"The risk or severity of adverse effects can be increased when Tapentadol is combined with Furosemide."
Clinical Note
moderateTapentadol + Bumetanide
Terminal elimination half-life: 15-60 hours (mean ~24 hours). Clinical context: Prolonged half-life supports once-daily dosing in opioid maintenance; accumulation occurs with repeated dosing due to long half-life.
Primarily renal: approximately 95% of the dose is excreted in urine (60% as tapentadol glucuronide, 15% as unchanged tapentadol, and 20% as other metabolites); less than 3% excreted in feces.
Primarily renal (40-50% as unchanged methadone and its metabolites, 15-20% as metadone-N-oxide), biliary/fecal (5-10%).
Category A/B
Category C
Opioid Agonist
Opioid Agonist
"The risk or severity of adverse effects can be increased when Tapentadol is combined with Bumetanide."